Table 2.

Characteristics of the Cohort Included in a Vaccine Safety Datalink Recombinant Zoster Vaccine Safety Study^a

	RZV Recipients (n = 647,307)		Historical ZVL Comparators (n = 732,152)		Well-Visit Comparators (n = 1,086,260)
Study Cohort Characteristic	No.	%	No.	%	No.	%
Age group, years
50–59	106,621	16	60,971b	8	270,963	25
60–69	258,030	40	475,516	65	373,996	34
70–79	207,812	32	144,377	20	299,177	28
≥80	74,844	12	51,288	7	142,124	13
Female sex	377,048	58	393,061	54	598,883	55
Health-care–seeking behavior
Dermatology visit during prior year	149,711	23	99,401	14	167,639	15
Optometry or ophthalmology visit during prior year	317,631	49	291,564	40	457,229	42
Receipt of ZVL vaccine at any time prior to RZV receipt or well-person visit	372,053	57	N/A	N/A	562,597	52
Comorbidity during prior year
Diabetes	116,226	18	141,905	19	185,698	17
Hypertension	281,370	43	301,720	41	401,758	37
Hyperlipidemia	313,644	48	293,134	40	410,616	38
Ischemic conditionc	52,305	8	55,836	8	74,396	7
Gastroesophageal reflux disease	130,149	20	106,904	15	175,640	16
Osteoarthritis	115,837	18	99,325	14	141,672	13
Atrial fibrillation	37,615	6	32,072	4	51,237	5
Herpes zoster	16,727	3	13,773	2	11,245	1
Dementia	13,257	2	6,962	1	25,429	2
Congestive heart failure	19,286	3	21,612	3	30,202	3
Chronic obstructive pulmonary disease	27,985	4	27,733	4	43,231	4
No. of concomitant vaccines
0	505,129	78	491,865	67	N/A	N/A
1	127,192	20	204,020	28	N/A	N/A
≥2	14,986	2	36,267	5	N/A	N/A

Abbreviations: N/A, not applicable; RZV, recombinant zoster vaccine; ZVL, zoster vaccine live.

^a January 2018–December 2019 for the RZV and well-person visit groups and January 2013–December 2017 for the historical ZVL group.

^b This group is shown here for descriptive purposes but was not included in subsequent analyses, since ZVL is only recommended for use among persons aged ≥60 years.

^c Includes ischemic heart disease, transient ischemic attack, and prior stroke.